BioSpace News Archive

QurAlis’ Biomarker-Driven Approach Attracts $88M in Series B

QurAlis has taken a biomarker-driven approach to treating ALS all the way to another bank deposit, closing an oversubscribed $88 million Series B round Thursday.

March 9, 2023
·
3 min read
·
Heather McKenzie
Drug Development

Acadia Wins FDA Approval for First Rett Syndrome Medicine

Acadia Pharmaceuticals announced the approval of Daybue (trofinetide) as the first and only drug to treat Rett Syndrome, a rare, neurodegenerative disorder affecting primarily girls.

March 9, 2023
·
3 min read
·
Heather McKenzie
Drug Development

AstraZeneca Notches Back-to-Back Late-Stage Wins in Lung Cancer

AstraZeneca reported positive data from both the Phase III ADAURA trial studying Tagrisso (osimertinib) and the Phase III AEGEAN studying Imfinzi (durvalumab) in NSCLC patients.

March 9, 2023
·
2 min read
·
Tristan Manalac
Bayer Plans to Double Down on US Pharma R&D in 2023

Bayer plans to substantially increase investment in U.S.-based pharmaceutical R&D, earmarking $1 billion to invest stateside in 2023.

March 9, 2023
·
2 min read
·
Kate Goodwin
Drug Development

Lilly’s Alzheimer’s Struggles Continue as Preclinical Disease Asset Fails Phase III

Data released Wednesday from the Phase III A4 study showed solanezumab fell short of its primary endpoint, failing to slow cognitive decline in patients with preclinical Alzheimer’s disease.

March 9, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Clene’s Nanocrystal ALS Treatment Bounces Back with Positive Data

Despite missing the initial mark, new analysis of Clene’s gold nanocrystal therapy from the HEALEY ALS trial indicates the asset still shows promise.

March 9, 2023
·
2 min read
·
Kate Goodwin
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug

QIAGEN N.V. announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia.

March 9, 2023
·
5 min read
Biotech Bay

Oxford BioTherapeutics to Announce New Fully Integrated ADC Engine at World ADC Conference 2023

Oxford BioTherapeutics Ltd. announced it will reveal its new fully integrated ADC engine, combining its internationally recognised target discovery and ADC development capabilities, at the 13th Annual World ADC Conference being held in London, UK, from 13 to 16 March 2023.

March 9, 2023
·
5 min read
Drug Development

AM-Pharma to Present Data From Phase 3 REVIVAL Study at Upcoming Scientific Conferences

AM-Pharma B.V. announced that Professor Peter Pickkers, M.D., Ph.D., principal investigator of the Phase 3 REVIVAL study, will present data from the study at two upcoming scientific conferences.

March 9, 2023
·
5 min read
Drug Development

GenFleet Therapeutics to Present Phase I Data for GFH312 at 2023 American Society for Clinical Pharmacology & Therapeutics Meeting

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the results from phase I study of GFH312 (RIPK1 inhibitor) monotherapy will be presented as a poster at the 2023 ASCPT Meeting in Atlanta on March 22nd.

March 9, 2023
·
4 min read